Company intelligence / Profile preview

TB Alliance

New York City, New York, United Statestballiance.org ↗

Ownership: Private
Employees: ~50
Development stage: Commercial

Overview

TB Alliance has developed and commercialized pretomanid, a novel small-molecule anti-tuberculosis drug approved by the FDA in August 2019 as part of a three-drug regimen for XDR-TB and certain cases of MDR-TB. The organization manages the largest pipeline of new TB drugs globally, with multiple candidates at various clinical stages. Its mission is to ensure that new treatments are affordable and accessible worldwide

Therapeutic areas: Infectious Diseases
Modalities: Small molecule
Industry: Biotech

Drug pipeline

13 assets

pretomanid

Approved

12 more assets in the full pipeline.

Request access →

Partnerships

Janssen Pharmaceutica NV/Tibotec/Johnson & Johnson – collaboration on bedaquiline/TMC207 developmentBayer Healthcare – partnership on moxifloxacin development for TBBill & Melinda Gates Foundation – major funder

Beyond the preview

Go deeper on TB Alliance.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TB Alliance.

Explore the full profile